Aperio Group’s MediciNova MNOV Stock Holding History

Aperio Group’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,270	Closed	-$12K	–	2580
2019 Q2	$12K	Buy	+1,270	New	+$13.4K	﹤0.01%	2763

Other funds holding MNOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aperio Group's MNOV Position: Q3 2019 in Review

Aperio Group sold out of MediciNova (MNOV) in Q3 2019, closing a stake of 1,270 shares — an estimated $12K sold.

Aperio Group first reported a position in MNOV in Q2 2019 and held it in 1 quarter. The position peaked at $12K in Q2 2019. 49 funds tracked by Wall St. Rank hold MNOV as of Q3 2019.

Aperio Group reported no remaining MediciNova position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 1,270 MediciNova shares in Q3 2019, an estimated $12K.
Aperio Group first reported a position in MediciNova in Q2 2019 and held it in 1 quarter.
Aperio Group's MediciNova position peaked at $12K in Q2 2019.
49 funds tracked by Wall St. Rank held MediciNova as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.